Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: Role of autophagy

Clinical and Experimental Pharmacology and Physiology

Volumn 41, Issue 12, 2014, Pages 995-1002

  Zhang, Yao Jun ^a   Yang, Shao Hua ^b   Li, Ming Hui ^a   Iqbal, Javaid ^c,d   Bourantas, Christos V ^d   Mi, Qiong Yu ^a   Yu, Yi Hui ^a   Li, Jing Jing ^a   Zhao, Shu Li ^a   Tian, Nai Liang ^a   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Department of Organ Transplantation   (China)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Autophagy; Berberine; Left ventricular remodelling; Myocardial infarction

Indexed keywords

BECLIN 1; BERBERINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOW DRUG DOSE; NONHUMAN; PROTEIN EXPRESSION; RAT; SURVIVAL RATE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MYOCARDIAL INFARCTION; PROCEDURES; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; AUTOPHAGY; BERBERINE; ECHOCARDIOGRAPHY; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84912574268     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12309     Document Type: Article

References (39)

1. Waldreus N, Hahn RG, Jaarsma T. Thirst in heart failure: A systematic literature review. Eur. J. Heart Fail. 2013; 15: 141-9.
2. Gerczuk PZ, Kloner RA. An update on cardioprotection: A review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 2012; 59: 969-78.
3. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their carers: A 3-year follow-up study assessing hospitalization and mortality. Eur. J. Heart Fail. 2010; 12: 1002-8.
4. Burns RJ, Gibbons RJ, Yi Q et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J. Am. Coll. Cardiol. 2002; 39: 30-6.
5. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72.
6. Velagaleti RS, Pencina MJ, Murabito JM et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008; 118: 2057-62.
7. Mehta PA, Dubrey SW, McIntyre HF et al. Improving survival in the 6 months after diagnosis of heart failure in the past decade: Population-based data from the UK. Heart 2009; 95: 1851-6.
8. Hernandez AF, Hammill BG, O'Connor CM, Schulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J. Am. Coll. Cardiol. 2009; 53: 184-92.
9. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur. J. Heart Fail. 2014; 16: 143-50.
10. Parajuli N, Yuan Y, Zheng X, Bedja D, Cai ZP. Phosphatase PTEN is critically involved in post-myocardial infarction remodeling through the Akt/interleukin-10 signaling pathway. Basic Res. Cardiol. 2012; 107: 248.
11. Hojo Y, Saito T, Kondo H. Role of apoptosis in left ventricular remodeling after acute myocardial infarction. J. Cardiol. 2012; 60: 91-2.
12. Mourouzis I, Mantzouratou P, Galanopoulos G et al. Dose-dependent effects of thyroid hormone on post-ischemic cardiac performance: Potential involvement of Akt and ERK signalings. Mol. Cell. Biochem. 2012; 363: 235-43.
13. Kanamori H, Takemura G, Goto K et al. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-activating AMP kinase pathway. Am. J. Pathol. 2013; 182: 701-13.
14. Liu Y, Gao XM, Fang L et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 2011; 31: 834-41.
15. Webster KA. Mitochondrial membrane permeabilization and cell death during myocardial infarction: Roles of calcium and reactive oxygen species. Future Cardiol. 2012; 8: 863-84.
16. Ovize M, Baxter GF, Di LF et al. Postconditioning and protection from reperfusion injury: Where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc. Res. 2010; 87: 406-23.
17. Kanamori H, Takemura G, Goto K et al. The role of autophagy emerging in postinfarction cardiac remodelling. Cardiovasc. Res. 2011; 91: 330-9.
18. Buss SJ, Muenz S, Riffel JH et al. Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 2009; 54: 2435-46.
19. Kanamori H, Takemura G, Goto K et al. Autophagy limits acute myocardial infarction induced by permanent coronary artery occlusion. Am. J. Physiol. Heart Circ. Physiol. 2011; 300: H2261-71.
20. Takagi H, Matsui Y, Sadoshima J. The role of autophagy in mediating cell survival and death during ischemia and reperfusion in the heart. Antioxid. Redox Signal. 2007; 9: 1373-81.
21. Qi MY, Feng Y, Dai DZ, Li N, Cheng YS, Dai Y. CPU86017, a berberine derivative, attenuates cardiac failure through normalizing calcium leakage and downregulated phospholamban and exerting antioxidant activity. Acta Pharmacol. Sin. 2010; 31: 165-74.
22. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 2003; 92: 173-6.
23. Wang YY, Li HM, Wang HD et al. Pretreatment with berberine and yohimbine protects against LPS-induced myocardial dysfunction via inhibition of cardiac I-[kappa]B[alpha] phosphorylation and apoptosis in mice. Shock 2011; 35: 322-8.
24. Wang N, Feng Y, Zhu M et al. Berberine induces autophagic cell death and mitochondrial apoptosis in liver cancer cells: The cellular mechanism. J. Cell. Biochem. 2010; 111: 1426-36.
25. Wan X, Chen X, Liu L et al. Berberine ameliorates chronic kidney injury caused by atherosclerotic renovascular disease through the suppression of NFkappaB signaling pathway in rats. PLoS ONE 2013; 8: e59794.
26. Li H, Xie YH, Yang Q et al. Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats. PLoS ONE 2012; 7: e48872.
27. Zhang YJ, Zhang XL, Li MH et al. The ginsenoside rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis. J. Cardiovasc. Pharmacol. 2013; 62: 50-7.
28. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: An analysis from preclinical evidences to clinical trials. Expert Opin. Biol. Ther. 2012; 12: 1113-24.
29. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004; 203: 127-37.
30. Zheng LY, Zhou ZY, Tao DC, Lan TJ. Protective effect of berberine on cardiacmyocyte injured by ischemia reperfusion. J. Sichuan Univ. (Med. Sci. Edi.) 2003; 34: 452-4.
31. Ho JW, Jie M. Pharmacological activity of cardiovascular agents from herbal medicine. Cardiovasc. Hematol. Agents Med. Chem. 2007; 5: 273-7.
32. Lv X, Yu X, Wang Y et al. Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression. PLoS ONE 2012; 7: e47351.
33. Porrello ER, Delbridge LM. Cardiomyocyte autophagy is regulated by angiotensin II type 1 and type 2 receptors. Autophagy 2009; 5: 1215-6.
34. Wagner C, Tillack D, Simonis G, Strasser RH, Weinbrenner C. Ischemic post-conditioning reduces infarct size of the in vivo rat heart: Role of PI3-K, mTOR, GSK-3beta, and apoptosis. Mol. Cell. Biochem. 2010; 339: 135-47.
35. Niedzwiedzka-Rystwej P, Tokarz-Deptula B, Deptula W. Autophagy in physiological and pathological processes-selected aspects. Pol. J. Vet. Sci. 2013; 16: 173-80.
36. Meijer AJ, Codogno P. Signalling and autophagy regulation in health, aging and disease. Mol. Aspects Med. 2006; 27: 411-25.
37. Sakiyama T, Musch MW, Ropeleski MJ, Tsubouchi H, Chang EB. Glutamine increases autophagy under Basal and stressed conditions in intestinal epithelial cells. Gastroenterology 2009; 136: 924-32.
38. Haussinger D, Schliess F, Dombrowski F, Vom DS. Involvement of p38MAPK in the regulation of proteolysis by liver cell hydration. Gastroenterology 1999; 116: 921-35.
39. Yang SS, Liu YB, Yu JB et al. Rapamycin protects heart from ischemia/reperfusion injury independent of autophagy by activating PI3 kinase-Akt pathway and mitochondria K(ATP) channel. Pharmazie 2010; 65: 760-5.